Chemotherapy by artemether, which was one of the qinghaosu (QHS, artemisinin) derivatives, was attempted in a case of severe falciparum malaria.
A Japanese 28 years old male, after making round trip in Africa, started fever attack one week before coming back to Tokyo. On the day of admission, he developed fever at 41°C, and asexual forms of
P. falciparum were observed in the peripheral blood of the patient at a density of 17% of erythrocytes. His consciousness was turbid; cerebral malaria was suspected. Liver was palpable by two finger breadth but spleen was not palpable. Slight jaundice was observed. On the laboratory findings, anemia was remarked and a considerable degree of dysfunction of liver and kidney was also noted. By
in vitro chloroquine susceptibility test, the isolate showed no resistance to chloroquine.
Quinine has been used as the drug of first choice to treat severe malaria. However we considered artemether is the antimalarial of higher priority than quinine especially in the treatment of patients with dysfunctions of liver, kidney and CNS, because side effects by quinine occasionally involve those organs. In addition, the half-life of quinine in the blood is 2.5 times as long as that of artemether, which again might endanger such patients. While artemether is documented to be remarkably well tolerated in man and also appears to be safe in the cases complicated by heart, liver, and renal disorders, because of the short half-life and rapid action of the derivative.
Two hundred milligram of artemether was administered on first dose intramusculary followed by 100 mg/dose at intervals of 12 hours to the amount totaling 1, 000 mg. The asexual stage parasites from blood films were eliminated in 66 hours after starting treatment, therefore, the patient already recovered from severity when administered artemether amounted to 600 mg which is the standard total dosage. When the clinical signs were away, the patient was supplemented by chloroquine administration, because recrudescence rate of artemether within one month is recorded higher than 10 per cent.
Most Japanese are non-immuners to malaria, hence tend to develop severe malaria if treatments delay. Artemether seems to be a promising new antimalarial with high potentiality to cure such patients.
View full abstract